All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Betta Pharmaceuticals Co. Ltd. has described hypoxia-inducible factor-2α (HIF-2α; EPAS1) inhibitors reported to be useful for the treatment of Von Hippel-Lindau disease, cancer, autoimmune disease and inflammatory disorders.
